Sepsis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 The Sepsis Therapeutics Market is forecast to Show High Growth until 2017 GlobalData has estimated the value of the global sepsis therapeutics market to be $5 billion in 2010. It is forecast to grow at a CAGR (Compound Annual Growth Rate) of 5.8% for the next seven years to reach $7.4 billion by 2017. The market had grown at a CAGR of 3.4% during the historic period (2005-2010). The major breakthrough in the sepsis therapeutics market was the approval of Xigris (drotrecogin alfa [activated]) by the FDA (Food and Drug Administration) and the EMEA (European Medicines Agency) in 2001. Coming up in the near future, Talactoferrin alfa and CytoFab are the molecules in late stage development with better efficacy and safety for the treatment of sepsis, and hence they are expected to increase the patient compliance rate and decrease the mortality rate. The increasing patient population and the expected launch of a small number of biologics and newer therapies during the forecast period will drive the market growth. GlobalData has found the existing competition in the sepsis therapeutics market to be weak. Currently, Xigris is the only prescribed drug for the treatment of sepsis. Mortality is high in patients with septic shock and Xigris in the sepsis segment aims to reduce the number of deaths. However, due to its severe adverse effects of bleeding the usage of the drug is declining and therefore the unmet need remains high. Toraymyxin, a device containing antibiotics, is in Phase III in the US and after it gets approval it could be used to reduce the mortality for patients with severe sepsis. The device is already approved in Japan and other European countries. There are a huge number of patients waiting for newer therapies which would decrease the mortality rate. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Sepsis-Therapeutics-PipelineAssessment-and-Market-Forecasts-to-2017&ReportType=Industry_R GlobalData has found that the pipeline for sepsis therapeutics is strong, with 28 molecules in various stages of clinical development. There are 27 first-in-class molecules over all of the phases of development, which means that 97% of the pipeline molecules have a novel mechanism of action. Talactoferrin alfa, CytoFab are the promising molecules in the late stage pipeline. These are expected to have better efficacy and safety for the treatment of sepsis. The molecules will decrease the mortality rate and increase the patient compliance rate for all sepsis patients. Both of the drugs are biologics and are expected to be highly priced. Toraymyxin (device with antibiotic polymyxin B) is also in Phase III and is already approved in Japan and other European countries. The device is expected to be marketed in Canada market by this year and if approved by the FDA it would help in reducing the mortality rate. GlobalData, the industry analysis specialist, has released its new report, “Sepsis Therapeutics Pipeline Assessment and Market Forecasts to 2017�. The report is an essential source of information and analysis on the global sepsis market. The report identifies the key trends shaping and driving the global sepsis market. The report also provides insights on the prevalent competitive landscape and the
emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global sepsis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Sepsis-Therapeutics-Pipeline-Assessment-andMarket-Forecasts-to-2017&ReportType=Industry_R Visit our report store: http://www.globaldata.com/reportstore For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782